Revance(US:RVNC) Prnewswire·2025-02-04 10:45Core Viewpoint - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted exclusive rights to market and distribute Teoxane's dermal fillers [2] - Allegations include that this breach increased the risk of litigation and caused monetary and reputational harm to the company [2] - The lawsuit asserts that these issues led to the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as a top securities litigation firm in the United States [4] - The firm has over 70 employees and extensive expertise in complex securities litigation [4]